Similarly, in the IM power 110 study, first‐line atezolizumab monotherapy is associated with better outcomes compared to chemotherapy in advanced NSCLC patients with high PD‐L1 expression.5 This evidence concerns the gene CD274 and non-small cell lung carcinoma.